tirzepatide surmount 1 ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction SURMOUNT-5: Tirzepatide Bests Semaglutide in
Description
The medication is typically prescribed for periods of 12 weeks or less because tolerance can develop and the stimulant effects carry cardiovascular risks with long-term use
Some experience mild acid reflux or changes in bowel habits
Neuroinflammation 8 , 9 (2011)
People who stop taking GLP-1 medications (Ozempic, Wegovy, Mounjaro) regain weight way faster than those who lost it through strength training and better nutrition habits
Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work
& Kent, L
